Morgan Stanley Taysha Gene Therapies, Inc. Put Options Transaction History
Morgan Stanley
- $1.23 Trillion
- Q1 2024
Put Options
0 transactions
Quarter | Operation | Price Per put | puts change | puts Held | SEC Form |
---|
Others Institutions Holding TSHA
# of Institutions
111Shares Held
109MCall Options Held
108KPut Options Held
158K-
Avoro Capital Advisors LLC New York, NY18.7MShares$40.1 Million0.65% of portfolio
-
Rtw Investments, LP New York, NY18.6MShares$40 Million0.86% of portfolio
-
Vr Adviser, LLC New York, NY9MShares$19.4 Million2.22% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.92MShares$12.7 Million0.0% of portfolio
-
Baker Bros. Advisors LP New York, NY4MShares$8.61 Million0.15% of portfolio
About Taysha Gene Therapies, Inc.
- Ticker TSHA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 48,359,500
- Market Cap $104M
- Description
- Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for th...